RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 TARGET
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 7
OP 7
DO 10.1177/1559897715588276
UL http://mdc.sagepub.com/content/15/9/7.1.abstract
AB Treatment with AVP-825 significantly reduces headache-associated burden and functional disability. Improvements are seen as early as 45 minutes after treatment, with significant percentages of patients reporting either mild or no disability by 120 minutes postdose. Headache response, improvement in functioning, and reduction in disability corresponded with the rates of patient-reported meaningful relief.